Related Experiment Videos
Trials to slow progression and prevent disease onset
1Department of Neurosciences, University of California San Diego School of Medicine, La Jolla 92093-0624, USA.
Journal of Neural Transmission. Supplementum
|August 29, 2000
Summary
Current Alzheimer's disease (AD) treatments are symptomatic. New therapies aim to slow progression or delay onset by targeting amyloid, inflammation, and other factors, with prevention trials also underway.
Area of Science:
- Neurology
- Pharmacology
- Gerontology
Background:
- Current Alzheimer's disease (AD) treatments primarily manage symptoms and enhance cognition.
- Limited interventions, such as selegiline and vitamin E, have shown potential in delaying disease progression to key endpoints.
Purpose of the Study:
- To review current and emerging treatment strategies for Alzheimer's disease.
- To highlight ongoing research in disease modification and prevention.
Main Methods:
- Review of existing literature on Alzheimer's disease therapeutics.
- Summary of clinical trial categories targeting disease progression and primary prevention.
Main Results:
- Existing AD treatments offer symptomatic relief but do not halt disease progression.
- Numerous therapeutic classes are under investigation, including antioxidants, anti-inflammatory agents, growth factors, hormones, and amyloid-targeting drugs.
Conclusions:
- Future Alzheimer's disease treatments focus on slowing progression or delaying onset.
- Active research includes primary prevention trials and interventions for mild cognitive impairment to prevent AD development.